Alternative Insulin Regimens

Introduction to Alternative Regimens

The American Diabetes Association recommends switching to a basal-bolus regimen using available insulin lispro or insulin aspart as rapid-acting prandial insulin twice daily before breakfast and dinner, combined with NPH insulin to provide basal coverage, when Humalog 75/25 is unavailable 1, 2

Insulin lispro and insulin aspart have onset of action at 0.25-0.5 hours, peak at 1-3 hours, and duration of 3-5 hours, making them clinically interchangeable 5

The American Association of Clinical Endocrinologists recommends calculating the total daily dose from the patient's current Humalog 75/25 regimen and distributing it as 50% NPH insulin and 50% rapid-acting insulin lispro or aspart, with NPH split into morning and evening doses 2, 3
The Endocrine Society suggests administering rapid-acting insulin 0-5 minutes before meals to maintain the convenience of the original Humalog 75/25 timing 4

The American Diabetes Association recommends calculating the current total daily dose from Humalog 75/25 and converting to basal-bolus by giving 50% of TDD as NPH insulin and 50% as rapid-acting insulin lispro or aspart, divided before breakfast and dinner 1, 2, 4

The American Association of Clinical Endocrinologists recommends increasing blood glucose monitoring frequency during the first 1-2 weeks after conversion and adjusting doses based on patterns, with a focus on fasting glucose, 2-hour postprandial glucose, and hypoglycemia monitoring 2, 3
The Endocrine Society suggests adjusting doses by 10-20% based on glucose patterns, with increases in evening NPH for elevated fasting glucose and increases in morning NPH for elevated pre-dinner glucose 2, 4

The American Diabetes Association advises against using equal morning and evening doses, as this increases the risk of nocturnal hypoglycemia, and recommends a 2/3 vs 1/3 distribution 2, 3
The American Association of Clinical Endocrinologists warns against mixing insulins in the same syringe, as this can lead to unpredictable pharmacokinetics and potentially dangerous outcomes 2